Literature DB >> 2873545

[Local subjective tolerance of levobunolol and metipranolol in a double-blind comparative study in patients with increased intraocular pressure].

M Ober, A Scharrer, G D Novack, J C Lue.   

Abstract

We evaluated the ocular comfort of 0.5% levobunolol hydrochloride and 0.6% metipranolol hydrochloride ophthalmic solutions in a randomized, double-masked, paired-comparison clinical trial. The drugs were given twice daily for 7 days to 16 patients with open-angle glaucoma or ocular hypertension. Patients rated comfort in terms of the severity of burning and/or stinging. For both drugs, the severity rating of ocular discomfort was low, averaging between 1 and 2 on a scale of 0-10. At initial and follow-up visits, the mean severity rating of burning or stinging with metipranolol was 2, slightly greater than the mean score of 1 with levobunolol. At 55% (26 of 47) of the patient visits, the patients rated levobunolol as more comfortable than metipranolol. Metipranolol (Betamann; Mann) was rated as more comfortable than levobunolol at only 9% (4 of 47) of the patient visits. The duration of burning and stinging was also rated as longer lasting with metipranolol treatment than with levobunolol (Vistagan; Pharma-Allergan) treatment. Although little ocular discomfort was reported for either drug, the majority of the patients tested rated levobunolol the more comfortable of the two drugs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2873545     DOI: 10.1159/000309631

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  3 in total

Review 1.  Ocular metipranolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in glaucoma and ocular hypertension.

Authors:  P E Battershill; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

2.  Levobunolol and metipranolol: comparative ocular hypotensive efficacy, safety, and comfort.

Authors:  G K Krieglstein; G D Novack; E Voepel; G Schwarzbach; U Lange; K P Schunck; J C Lue; E P Glavinos
Journal:  Br J Ophthalmol       Date:  1987-04       Impact factor: 4.638

Review 3.  Ocular levobunolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  J P Gonzalez; S P Clissold
Journal:  Drugs       Date:  1987-12       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.